LipoScience Announces Agreement With Scripps Health For First California Placement Of Vantera® Clinical Analyzer

RALEIGH, N.C., Nov. 25, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ:  LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced an agreement to place the Vantera^® Clinical Analyzer within Scripps Health facilities. The agreement, which marks the first placement of the Vantera Clinical Analyzer in the state of California, will make NMR lipoprotein testing on the analyzer accessible to customers of Scripps Health.

The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. Such analysis provides the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information from a simple blood test. LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer and a key component of LipoScience's NMR LipoProfile^® test.

Adoption and decentralization of the Vantera Clinical Analyzer into clinical laboratories will ultimately provide widespread access to the NMR LipoProfile test, reduce sample processing turnaround time and provide value to physicians focused on delivering quality patient care and personalized management of CVD. To date, over 10 million NMR LipoProfile tests have been ordered.

"LDL particle number is increasingly understood to be a more clinically reliable measure of LDL and we believe it should be a key component of cardiovascular disease management," said Michael Quigley, M.D., medical director of Scripps Medical Laboratory. "By placing the Vantera Clinical Analyzer within our facilities, Scripps Health will be able to help physicians devise personalized cardiovascular risk-reduction strategies tailored to individual patients' needs." 

"We are excited to announce that Scripps Health is the first California-based laboratory to place the Vantera Clinical Analyzer and offer the NMR LipoProfile test," said Peter Riefenhauser, vice president of marketing at LipoScience. "This placement is an important development for physicians and their patients as we continue to drive NMR diagnostics as a clinical standard of care." 

About LipoScience, Inc.
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is striving toward the NMR LipoProfile® test becoming the preferred choice by physicians for the management of cardiovascular disease. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include expectations regarding the capabilities and availability of the Vantera Clinical Analyzer and the Company's ability to increase and sustain demand for its NMR LipoProfile test, as well as the Company's plans for future diagnostic tests on the Vantera platform.  The achievement or success of the matters covered by such forward-looking statements involve risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, the Company's results could differ materially from the results expressed or implied by the forward-looking statements it makes.  These risks and uncertainties include, but are not limited to, risks associated with the receptiveness of third-party laboratories with respect to the placement of Vantera Clinical Analyzers at their facilities, the Company's ability to expand its sales and marketing capabilities in order to increase demand for the NMR LipoProfile test and any future tests that it may develop, the Company's ability to compete with other diagnostic testing methods that may be more widely accepted and the Company's ability to secure regulatory clearance by the FDA of the non-cleared portions of the NMR LipoProfile test.  Further information on these and other factors that could affect the Company's results is included in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time.  These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com.  The statements made in this release are based on information available to LipoScience as of the date of this release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

SOURCE LipoScience, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED